

Dopamine and memory dedifferentiation in aging

Article (Accepted Version)

Abdulrahman, Hunar, Fletcher, Paul C, Bullmore, Edward and Morcom, Alexa M (2017) Dopamine and memory dedifferentiation in aging. *NeuroImage*, 153. pp. 211-220. ISSN 1053-8119

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/82814/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Dopamine and memory dedifferentiation in aging

Abbreviated title: Dopamine and memory dedifferentiation in aging

Hunar Abdulrahman⁽¹⁾, Paul C. Fletcher^(2,3), Edward Bullmore^(2,3,4), Alexa M. Morcom⁽⁵⁾

⁽¹⁾ MRC Cognition & Brain Sciences Unit, University of Cambridge, Cambridge, CB2 7EF, UK

⁽²⁾ Brain Mapping Unit, Department of Psychiatry, and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Robinson Way, Cambridge CB2 0SZ, UK

⁽³⁾ Cambridge and Peterborough Foundation trust, Fulbourn Hospital, Cambridge CB21 5EF

⁽⁴⁾ GlaxoSmithKline, ImmunoPsychiatry, Alternative Discovery & Development, Stevenage SG1 2NY, UK

⁽⁵⁾ Centre for Cognitive Ageing and Cognitive Epidemiology, Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK

Correspondence:

Dr. Hunar Abdulrahman

MRC Cognition & Brain Sciences Unit

15 Chaucer Road

Cambridge, CB2 7EF

Phone: +44 (0) 1223 355 294

Email: hunar.abdulrahman.@mrc-cbu.cam.ac.uk

1 **Abstract**

2 The dedifferentiation theory of aging proposes that a reduction in the specificity of neural
3 representations causes declines in complex cognition as people get older, and may reflect a
4 reduction in dopaminergic signaling. The present pharmacological fMRI study investigated episodic
5 memory-related dedifferentiation in young and older adults, and its relation to dopaminergic
6 function, using a randomized placebo-controlled double-blind crossover design with the agonist
7 Bromocriptine (1.25 mg) and the antagonist Sulpiride (400 mg). We used multi-voxel pattern
8 analysis to measure memory specificity: the degree to which distributed patterns of activity
9 distinguishing two different task contexts during an encoding phase are reinstated during memory

10 retrieval. As predicted, memory specificity was reduced in older adults in prefrontal cortex and in
11 hippocampus, consistent with an impact of neural dedifferentiation on episodic memory
12 representations. There was also a linear age-dependent dopaminergic modulation of memory
13 specificity in hippocampus reflecting a relative boost to memory specificity on Bromocriptine in
14 older adults whose memory was poorer at baseline, and a relative boost on Sulpiride in older better
15 performers, compared to the young. This differed from generalized effects of both agents on task
16 specificity in the encoding phase. The results demonstrate a link between ageing, dopaminergic
17 function and dedifferentiation in the hippocampus.

18

19 **Keywords**

20 Aging; dedifferentiation; episodic memory; hippocampus; prefrontal cortex; dopamine

21 **Introduction**

22 The dedifferentiation theory of cognitive aging proposes that there is a loss of specificity of
23 neural representations as people become older. These pervasive changes are assumed to impact
24 predominantly on the complex cognitive functions which decline the most (Baltes and
25 Lindenberger, 1997; Li et al., 2001). Functional magnetic resonance imaging (fMRI) studies have
26 revealed widespread age-related reductions in the specificity of distributed cortical patterns of
27 activity elicited by different categories of visual stimuli (Carp et al., 2010b; Goh et al., 2010; Park
28 et al., 2004) and different actions (Carp et al., 2011). Preliminary evidence also supports the
29 prediction that dedifferentiation impacts on functions and regions which decline prominently in old
30 age: the visual category-specificity of cortical activity patterns correlates with with older adults'
31 fluid processing ability, and varies with working memory load in frontal and parietal cortex (Carp et
32 al., 2010a; Park et al., 2010; Payer et al., 2006). However, little is currently known about the
33 mechanisms of dedifferentiation, nor its impact on episodic memory, one of the cognitive functions
34 most affected by aging. We investigated whether memory representations are less specific in older
35 adults and explored the modulation of memory specificity by dopaminergic drugs.

36 Normal aging is accompanied by a marked decline in detailed recollection of events, and an
37 increase in false memory (Schacter et al., 1997; Spencer and Raz, 1995). These episodic memory
38 difficulties are typically attributed to declines in the integrity of the prefrontal cortex (PFC) and the
39 hippocampus (e.g., Head 2008; Yonelinas 2007). However, regional age-related changes may be
40 secondary to generalized neural changes such as dedifferentiation. The first aim of the present study
41 was to examine whether the specificity of episodic reinstatement differs according to age. Episodic
42 recollection is thought to involve hippocampal reactivation of stored memory traces which represent
43 events' particular sensory and cognitive properties (Alvarez and Squire, 1994; McClelland et al.,
44 1995). Consistent with this, functional imaging studies show that successful episodic memory
45 retrieval is accompanied by reinstatement of cortical activity associated with the original events
46 (Danker and Anderson, 2010). Studies using multi-voxel pattern analysis (MVPA) have further
47 shown that the specificity of this episodic reinstatement for particular tasks and categories of stimuli
48 varies with strategic memory search and with competition between relevant and irrelevant
49 memories, suggesting that it reflects the specificity of recollection (Kuhl et al., 2011; McDuff et al.,
50 2009). Using MVPA, St Laurent et al. (2014) recently showed less distinctive cortical reinstatement
51 in older adults for individual items. We examined the specificity of distributed patterns of
52 reinstatement for two different encoding task contexts involving semantic and phonological
53 processing (Johnson et al., 2009; Polyn et al., 2005). We then determined the degree to which
54 distinct task-related activity patterns present during encoding were reinstated during subsequent
55 retrieval, predicting that this measure of memory specificity would be reduced in older relative to
56 younger adults.

57 According to computational models, age-related dedifferentiation may reflect a reduction in
58 dopamine signaling and neural signal-to-noise in prefrontal cortex (PFC; Li et al., 2001), and
59 potentially elsewhere. Modeling dedifferentiation in this way reproduces disruption of episodic
60 binding functions found in older adults (Li et al., 2005). This is in line with wider evidence of a
61 'correlative triad' between aging, cognition and dopamine function (Bäckman et al., 2006). The
62 second aim of the present study was to extend the findings of our previous report, which examined
63 dopaminergic modulations of brain activity associated with successful episodic encoding across the

64 two encoding tasks (Morcom et al., 2010). The study had a cross-over placebo-controlled design, in
65 which we administered a dopamine agonist (bromocriptine) and an antagonist (sulpiride) to
66 manipulate dopamine signaling. Morcom et al. (2010) found age-related differences in
67 dopaminergic effects on activity associated with successful episodic encoding in PFC and
68 hippocampus. This dopaminergic sensitivity was most pronounced in the older adults with poorer
69 memory, consistent with the notion that dopaminergic decline impairs ability to encode new
70 memories. Specifically, there were reversed subsequent memory (subsequent forgetting) effects
71 within MTL in the older group: i.e., encoding phase activity predicted later forgetting rather than
72 remembering (Morcom et al., 2010). We proposed then that older adults may encode less distinctive
73 memory representations which do not support specific recollection (Morcom et al., 2010; Wagner
74 and Davachi, 2001).

75 This novel joint analysis of task-specific activity at encoding and its reinstatement at
76 retrieval allowed us directly to test the link between dopamine, aging and dedifferentiation of
77 episodic memory. We predicted that the expected age-related reduction in memory specificity
78 would vary with changes in dopamine signaling. If dopaminergic decline causes dedifferentiation,
79 loss of memory specificity should be dopamine-sensitive. Predictions about the nature of this
80 sensitivity were derived from the results of the successful encoding study (Morcom et al., 2010) and
81 the dopamine aging hypothesis. First, we expected that dopaminergic modulation of memory
82 specificity would track individual differences in memory ability in the older group, and that poorer
83 older performers would show greater dopamine sensitivity, distinguishing them from the young.
84 Second, we predicted that the dopaminergic effect on memory specificity would parallel that
85 previously reported for the univariate memory encoding (subsequent memory) effects. In addition,
86 if the reversed, subsequent forgetting, effects in the older group reflected impaired memory
87 specificity as proposed by Morcom et al. (2010), then Bromocriptine should reduce memory
88 specificity in poorer older performers just as it enhanced subsequent forgetting effects.

89 **Methods**

90 **Subjects**

91 Sixteen younger (7 female, mean age = 24.9, SD = 4.7 years) and sixteen older adults (9
92 female, mean age = 66.9, SD = 3.3 years) contributed data. These comprised all subjects from the
93 previous report on the encoding data, as well as 1 young and 3 older subjects who had not provided
94 sufficient data for that event-related analysis, and 1 older participant who contributed data only for
95 the Placebo session. An additional 3 older subjects and 1 young were excluded due to missing
96 Placebo session data (3 with data acquisition or storage issues, 1 withdrew). Therefore, the Placebo
97 condition analyses included 16 young and 16 older subjects, and the drug analyses included samples
98 of 16 and 15. A further older subject was also excluded from analyses of covariance due to an
99 outlier value for the performance covariate, yielding sample sizes of 16 and 14 (see Results: Task
100 Specificity and Feature Selection). Volunteers were screened on initial telephone contact using a
101 standard questionnaire. The exclusion criteria were a history of any significant psychiatric or
102 physical condition which was likely to affect the brain or cerebral vasculature, current vasoactive or
103 neurotropic medication, and contraindications to the study drugs or to MRI. Each subject also had
104 an electrocardiogram prior to taking part in functional MRI scanning, reviewed by a physician, as
105 well as a structural scan. The groups were matched on years of education (in young, mean = 4.6, SD

106 = 2.6; in old, mean = 4.0, SD = 3.0; $t < 1$). Estimated verbal IQ using the National Adult Reading
107 Test (Nelson, 1982) was slightly higher in the older group as expected (Backman and Nilsson,
108 1996); for young, mean = 112, SD = 6.0; for old, mean = 118, SD = 6.5, $t(34) = 2.96$, $p = .006$; for
109 details see (Morcom et al., 2010).


110 **Experimental Design and Task**

111 Subjects took part in 3 experimental sessions in which they received Sulpiride 400 mg,
112 Bromocriptine 1.25 mg, or a Placebo orally, in a randomized double-blind crossover design. The
113 scanned episodic memory task commenced after 3 h, and comprised a study (encoding) phase,
114 followed by 2 test (retrieval) phase blocks. To avoid nausea within the double-blind procedure, the
115 study drug was given with 10 mg of the peripheral dopamine antagonist Domperidone (Reddymasu
116 et al. 2007). Subjects were also asked to eat beforehand. For Sulpiride the mean time to maximal
117 plasma concentration is about 3 h, and it has a plasma half-life of around 12 h, and oral
118 bioavailability of about 35%. Plasma prolactin concentration is maximal after about 1 h, then
119 declines slowly (Wiesel et al. 1982; von Bahr et al. 1991; Caley and Weber 1995). Bromocriptine's
120 central effects are also long lasting, though somewhat slower to onset than those of Sulpiride, with
121 measurable effects from as early as 1½ h post-dose which maximal after 3 h and persist for some
122 time (Luciana et al. 1998; Muller et al. 1998; Oranje et al. 2004). fMRI data acquisition began at
123 about 3-h post-dose and the sessions were separated by a minimum washout period of a week.
124 Subjects were randomly allocated to each of 6 possible counterbalanced session orders. After
125 exclusions, there were minor imbalances in session ordering between and across age groups. The
126 main analyses are reported with the full N, but we conducted check analyses to rule out possible
127 confounds of session effects: none were found, and effects were if anything more robust once
128 session ordering was balanced. Details of these check analyses are given in the Supplementary
129 Material.

130 Study and test stimuli were 4-9 letter nouns of 1-3 syllables from the CELEX database
131 (<http://www.ru.nl/celex/>; for details see (Morcom et al., 2010). The paradigm is illustrated in Figure
132 1. The study phase consisted of 16 “mini-blocks” of 15 trials each. Subjects performed two different
133 orienting tasks, one involving a semantic and one a phonological judgment. Semantic and
134 phonological mini-blocks alternated and each pair was followed by 21 s fixation. This task ordering
135 was counterbalanced across subjects. Semantic mini-blocks were preceded by the cue “Living?”
136 and subjects judged whether each word referred to a living or a non-living thing. Phonological mini-
137 blocks were preceded by the cue “Syllables?”, and subjects judged whether each word had an even
138 or an odd number of syllables. In both tasks half the items were animate and half inanimate, and of
139 each of these, half had an odd and half an even number of syllables. Items were distributed
140 randomly across mini-blocks. Words were shown center-screen in white uppercase Arial font on a
141 black background. The stimulus onset asynchrony (SOA) at study was 3000 ms, with stimuli on
142 screen for 600 ms followed by fixation.

143 The test phase consisted of two sessions, each including 18 mini-blocks of 10 trials. The
144 first session immediately followed the study phase (after a brief verbal interaction to prevent
145 rehearsal), followed by the second after an unrelated 6 min task. Subjects were told that in the mini-
146 blocks preceded by the cue, “Remember living”, previously seen items had all been studied in the
147 Living/ Non-living task, whilst in those preceded by “Remember syllable,” they had all been
148 studied in the Syllable task. Two thirds of the items had been studied and a third were new items,

149 distributed randomly across mini-blocks. Subjects judged whether they specifically recollected
 150 having studied the word (“Remembered”), whether they thought the word had been studied but it
 151 was just familiar (“Know”), or it was unstudied (“New”), using standard “Remember-Know”
 152 instructions (Gardiner, 1988). Mini-blocks alternated as at study, with 21s fixation after each pair.
 153 Test phase SOA was 4400 ms, with stimuli on screen for 600 ms followed by fixation.



154
 155 Figure 1. Paradigm design. Illustrates the mini-block structure of the study and test phases
 156 of the task. Note that not all mini-blocks are shown. See Experimental Design and Task for details.

157 MRI Data Acquisition and Preprocessing

158 Functional scans were acquired using a 3.0T Medspec S300 MRI system, with a gradient-
 159 echo echo planar (EPI) pulse sequence (TR = 1200 ms, TE = 27.5 ms, flip angle = 90°). Each EPI
 160 volume comprised 23 interleaved 4 mm thick axial slices angled to the intercommisural line, with a
 161 1mm inter-slice gap (64 x 64 pixels, in-plane resolution 3.125 mm). One encoding timeseries was
 162 acquired in the study phase (755 volumes), and two retrieval timeseries in the test phases (825
 163 volumes each). Seven “dummy” volumes were discarded at the start of each run. Outlier scans (with
 164 slices of > 5 standard deviations) were replaced with the mean of the 2 neighboring scans.

165 Initial preprocessing was done in SPM 5 (Wellcome Department of Cognitive Neurology,
 166 London, UK; <http://www.fil.ion.ucl.ac.uk/spm/software/spm5/>). Each timeseries was realigned
 167 spatially to the first volume, then normalized using nonlinear basis functions and resampled to 3 x 3
 168 x 3 mm voxels, using an EPI template based on the Montreal Neurological Institute (MNI)

169 reference brain (Cocosco et al., 1997) in the space of Talairach and Tournoux (Ashburner and
170 Friston, 1999; Talairach and Tournoux, 1988). No smoothing was performed. Further preprocessing
171 was carried out in MATLAB 7.6 (www.mathworks.com). Linear trends and frequencies below
172 1/180 Hz were removed from each time series using SPM5's high-pass filter function, and
173 timeseries normalized and scaled to a range of (-1,1) to allow for varying ranges of voxel activity
174 using the Princeton MVPA toolbox (Norman et al., 2006; Detre et.al, 2006;
175 <http://www.pni.princeton.edu/mvpa/>).

176 **Feature Selection**

177 Regions of interest (ROIs) were defined using WFU PickAtlas (<http://fmri.wfubmc.edu/>). ROIs
178 encompassed lateral PFC (inferior frontal gyrus (IFG) and middle frontal gyrus (MFG)), bilateral
179 hippocampus, and two areas previously shown to be engaged in episodic encoding during the
180 phonological orienting task (bilateral fusiform gyrus (FusG) and left superior occipital gyrus
181 (LSOG; Otten and Rugg, 2001)). Prefrontal ROIs were defined for each hemisphere separately
182 (LIFG, RIFG, LMFG & RMFG), as age-related differences in lateralization of memory function in
183 PFC were of potential interest (Morcom et al., 2003; Cabeza et al., 2009). Within each ROI, we
184 used the analysis of variance (ANOVA) feature selection utility in the Princeton toolbox to select
185 voxels showing the most significant differences between the two task conditions (semantic and
186 phonological) in each training (encoding phase) dataset. In order to check whether MVPA results
187 varied according to the threshold used for feature selection, we generated 3 separate feature sets for
188 each training dataset and ROI, comprising the 500, 150 and 50 most significant voxels. For each
189 ROI, the best performing feature set in the Placebo condition ridge regression analysis of task
190 specificity (encoding) effects was then used for all subsequent analyses of memory specificity and
191 drug effects, and for the correlation analysis (see Multi-voxel pattern analysis: age-related
192 differences, Task specificity, below).

193

194 **Multi-voxel pattern analysis using ridge regression**

195 We used multivariate pattern analysis (MVPA) to investigate the specificity of the patterns
196 of neural activity in the semantic and phonological encoding tasks (task specificity), and the
197 specificity with which information encoded using these two tasks was later retrieved (memory
198 specificity). Machine learning algorithms are now widely used to decode neural activity (Polyn et
199 al., 2005; Haynes and Rees, 2006; Kamitani and Tong, 2005). The fidelity with which they can
200 discriminate between two cognitive conditions provides a measure of the distinctiveness of different
201 patterns of neural activation. MVPA measures were computed for each subject and drug condition
202 using the Princeton MVPA toolbox (Norman et al., 2006; Detre et.al, 2006;
203 <http://www.pni.princeton.edu/mvpa/>). We used a penalized ridge regression algorithm because of its
204 sensitivity to intermediate activation values at training and at test, and its ability to compensate for
205 multicollinearity among features (Coutanche et al., 2011; Zhang and Yang, 2003; Poppenk and
206 Norman, 2012). This means that predictions of test set data are continuous rather than binary. To
207 assess the performance of the algorithm for each subject and drug session we calculated the
208 correlation coefficient of its predictions with the labels of the testing set using the inbuilt
209 performance metrics in the Princeton's toolbox, giving test set data values from -1 to 1 (chance =
210 0).

211 The first analyses assessed task specificity, i.e., the distinctiveness of neural patterns during
212 the two orienting tasks (semantic and phonological) within the study phase (encoding). Subjects'
213 encoding timeseries were subdivided into 8 equal subsets, each comprising one mini-block. To
214 account for hemodynamic lag the design was convolved with SPM8's canonical hemodynamic
215 response function (HRF). A ridge regression algorithm was then trained on 7 of these subsets and
216 tested on the 8th in a leave-one-out cross validation procedure with 8 iterations. Before application
217 of the algorithm to the test data, we ran a nested cross-validation procedure on the training data for
218 the Placebo condition to determine the optimum values for the ridge regression penalty parameter
219 which controls the maximum value of the sum of the squares of the voxel weights (Coutanche et al.,
220 2011). The optimum value within the range (0, 0.01, 0.1, 1, 10, 100, 1000, 10000) did not differ
221 between age groups (median value across ROIs and selected feature sets in both groups = 50;
222 interquartile range = 130, for Kruskal-Wallis tests in each ROI for selected feature sets, $p > .05$).
223 These individually determined penalty parameters were employed for all subsequent analyses.

224 Next, we investigated memory specificity in a combined study and test phase (encoding-
225 retrieval) analysis. Memory specificity was defined as the accuracy with which the algorithms
226 trained to discriminate between the encoding tasks were able to predict the retrieval task in each
227 ROI. For this analysis, all 8 pairs of encoding mini-blocks were used as training data, and each
228 retrieval phase's 9 pairs of mini-blocks served as 2 independent test runs. Memory specificity
229 measures were computed for both retrieval phases and the final measure of memory specificity for
230 each subject and drug session was the average performance of the ridge regressor across the two
231 phases. We note that because the encoding and retrieval mini-blocks contained different numbers
232 of trials (15 and 10, see above), this difference could contribute to lower values for memory
233 specificity than for task specificity. However, scan numbers and therefore data points available for
234 the ridge analysis were closely similar between the two phases (37.5 and 36.6). Moreover, an
235 overall difference between levels of task specificity and memory specificity was expected, since
236 they are assumed to reflect very different processes (see Introduction).

237 **Multi-voxel pattern analysis using correlation distance metric**

238 To check the reproducibility of the ridge regression results and for comparability with prior
239 studies of dedifferentiation in aging, we also measured memory specificity using a correlation
240 distance metric of neural distinctiveness (Carp et al., 2010b; Haxby et al., 2001). To allow for
241 hemodynamic delay, the fixation scans and the first 7 scans of each mini-block were discarded
242 giving 30 scans from each encoding and retrieval mini-block. Voxel values were then averaged
243 across the remaining scans in each semantic and phonological task mini-block for the study and test
244 phases, and across mini-blocks, and Pearson's product moment correlation coefficients computed
245 within and between tasks between the encoding phase and the retrieval phase. Memory specificity
246 was defined as the neural distinctiveness of activity patterns in the two different tasks across the two
247 phases of the episodic memory task. Memory specificity was calculated as the difference between
248 the average correlation within similar tasks (semantic encoding & semantic retrieval and
249 phonological encoding & phonological retrieval) and the average correlation between different
250 tasks (semantic encoding & phonological retrieval and phonological encoding & semantic
251 retrieval).

252 **Results**

253 **Task performance**

254 Detailed behavioral analyses of both study and test phases are included in the previous
255 report on the encoding data (Morcom et al., 2010). The pattern of findings was unchanged in this
256 larger sample. Performance on the two orienting tasks in the study phase did not differ according to
257 age group or drug condition, and both groups were highly accurate (90% for young, 89% for old).
258 In the test phase, the main index of memory performance was the discrimination index Pr for hits
259 and false alarms, collapsed over Remember and Know responses ($P_{Hit} - P_{False Alarm}$, Snodgrass and
260 Corwin, 1988). Pr did not differ between age groups on Placebo ($t < 1$), but there was a main effect
261 of drug with a linear trend ($F(1.8, 53.6) = 3.29$, $p = 0.049$; $F(1,29) = 4.26$, $p = .048$), mainly
262 reflecting a reduction in Pr on Sulpiride across both groups (mean = 0.43) relative to Placebo and
263 Bromocriptine (means = 0.47;). As in the previously reported sub-group of subjects, although this
264 effect did not interact with age ($F(1.8, 53.6) = 1.33$), it was driven mainly by a reliable linear effect
265 of drug in the older group taken alone. (Response bias, as indexed with Br ($P_{false alarm} / 1 - (P_{hit} - P_{false$
266 $alarm)$, (Snodgrass and Corwin, 1988), was also more liberal on Sulpiride (mean = 0.46; for Placebo
267 and Bromocriptine, means = 0.38 and 0.41; values > 0.5 indicate a relatively liberal bias to respond
268 “old”). Valid recollection and familiarity measures were available for a subset of 16 young and 13
269 older adults; these did not show reliable drug or group effects. In addition, the depth of processing
270 effect (better memory following semantic than phonological encoding (Craik and Lockhart, 1972)
271 did not differ between groups (mean probability of recollection = .53 and .28 in the young
272 respectively, and .50 and .27 in the older group; age effects n.s.) or as a result of the
273 pharmacological manipulation.

274 **Multi-voxel pattern analysis: age-related differences**

275 ***Task specificity***

276 Encoding phase task specificity in the Placebo condition was assessed using ridge
277 regression, and the results were also used to determine the optimal feature set size for each ROI for
278 the memory specificity and drug analyses (see Methods: Feature Selection). Results for all feature
279 sets are given in Supplementary Table 1. Cross-validation showed that the ridge algorithm
280 accurately discriminated between the semantic and phonological orienting tasks in all ROIs and
281 individual subjects ($p < 0.01$ for all). Average ridge accuracy across ROIs and feature sets was 0.78
282 in both the young and the older group (individual values ranged in the young group from 0.47 in
283 hippocampus to 0.98 in LIFG; in the older group, from 0.61 in hippocampus to 0.97 in LIFG).

284 The feature sets selected for each ROI were those with the maximum ridge performance on
285 Placebo which avoided any confounds of training set performance with age. Ridge accuracy was
286 better for larger feature sets in PFC, and this did not differ according to age. Therefore the 500
287 voxel feature sets were selected for memory specificity and drug analyses for these ROIs. In HC,
288 task specificity did not differ according to age and was greatest for the smaller feature sets, so these
289 were used for further analyses. In LSOG, the intermediate feature sets of 150 voxels were selected
290 to balance for the slight (but non-significant) increase in task specificity with # voxels in the older
291 group, and decrease in the young. In FusG, the 150 voxel feature set was selected, in which task
292 specificity was maximal and equivalent across age groups.

293 We also tested for associations between encoding phase task specificity and individual
294 differences in performance in the selected feature sets using ANCOVA with covariates of mean-

295 corrected Pr (see Results: Task Performance for definition) and the interaction of Pr x group (one
296 older subject was excluded from these analyses due to an outlier Pr value, > 2.5 SD from the mean).
297 These used Pr on Placebo as the covariate. These showed no associations in IFG or MFG (max F =
298 1.11). In posterior ROIs, behavioral associations were not reliable. Marginally significant main
299 effects of Pr in HC and FusG (p = .089; p = .063) reflected trends for task specificity to be greater
300 in better performers across both age groups; such trends could not complicate interpretation of any
301 age-related differences in memory specificity or in dopaminergic drug effects.

302

303 ***Memory specificity***

304 The results of the encoding-retrieval memory specificity analysis for the Placebo condition
305 are illustrated in Figures 2 and 3. For each ROI, ridge regression MVPA measures of memory
306 specificity for the selected feature sets were subjected to ANOVA with the factor of age group.
307 Further analyses with the additional factor of hemisphere tested for lateralization differences where
308 group differences were apparent in one ROI. We then tested for brain-behavior associations using
309 ANCOVA with the additional covariates of Pr (on Placebo) and Pr x group (see Task Specificity
310 and Feature Selection). Where covariate effects were present, we checked that these remained
311 significant when individual age was also included in the model, to rule out potential confounds
312 between performance- and age-related effects within groups (Hofer and Sliwinski, 2001). Except
313 where noted, this was the case. Following ridge analyses, we conducted replication analyses using
314 the correlation distance metric to assess consistency of results across MVPA metrics. These are
315 reported where there were positive findings from the ridge analysis. In summary, consistent age-
316 related differences in memory specificity were found in left PFC (LIFG and LMFG) and in
317 hippocampus.

318 Prefrontal cortex


319 In LIFG, memory specificity assessed with ridge regression was reduced in the older group
320 relative to the young ($F(1,30) = 9.09$, $p = 0.005$; for replication with correlation distance metric
321 ($F(1,30) = 15.80$; $p < 0.001$). In the older group, memory specificity was not significantly greater
322 than chance. In RIFG, group differences were not reliable ($F < 1$), but effects did not vary
323 significantly by hemisphere (for interaction with group, $F(1,30) = 1.48$, $p = 0.233$). Direct
324 comparison with encoding phase neural specificity measures also confirmed that the age-related
325 reduction in memory specificity was significantly greater than (non-significant) group differences in
326 task specificity at encoding (for group x task phase, $F(1,27) = 5.12$, $p = 0.032$). ANCOVA showed
327 no brain-behavior associations in LIFG. In RIFG, there was an association between memory
328 specificity and memory performance across groups (for ridge, $F(1,27) = 4.39$, $p = 0.049$; for
329 correlation, $F(1,27) = 6.65$, $p = 0.017$), although significance was reduced with age in the model,
330 for ridge, $F(1,26) = 1.92$, n.s.; for correlation, $F(1,26) = 5.86$, $p = 0.023$). Analysis across task
331 specificity and memory specificity ridge regression measures showed that this association with
332 performance was common to both, as reflected in a significant main effect of Pr ($F(1,27) = 5.02$, p
333 $= 0.017$; for task x Pr , $F(1,27) = 1.73$, n.s.).

334 Ridge analysis for left middle frontal gyrus (LMFG), as in LIFG, revealed a group
335 difference in memory specificity favouring the young ($F(1,30) = 7.08$, $p = 0.012$; for replication
336 analysis with correlation, $F(1,30) = 8.74$, $p = 0.006$), with ridge accuracy again at chance in the

337 older group. As in LIFG, direct comparison confirmed that the group difference was driven by
 338 memory specificity relative to encoding phase task-specificity (for task phase main effect, $F(1,30) =$
 339 7.94 , $p = 0.008$). In RMFG, as in RIFG, group differences were not significant ($F(1,30) = 1.2$, n.s.),
 340 but laterality analysis did not show reliable age-related differences by hemisphere. Brain-behavior
 341 analysis in MFG did not reveal any significant findings.

342 Because the correlation measure of neural distinctiveness is a function of correlations both
 343 within and between tasks, age differences in memory specificity could be driven by effects on
 344 within-task correlations, between-task correlations, or both (see (Carp et al., 2010b)). *Post hoc* tests
 345 in PFC showed that both within-task and between-task correlation effects contributed to the group
 346 differences in LIFG (main effect of group for within- $F(1,30) = 12.8$ $p = 0.001$; for between-,
 347 $F(1,30) = 13.1$, $p = 0.001$) and in LMFG (for within-, $F(1,30) = 9.3$ $p = 0.005$; for between-,
 348 $F(1,30) = 15.2$, $p < 0.001$).

349



350
 351 Figure 2. Age-related differences in memory specificity (Placebo session). ROIs are overlaid on the T1 MNI template
 352 from MRIcron (<http://www.mccauslandcenter.sc.edu/mricro/mricron/>; sections at $x = 30$, $y = 18$, $z = 12$). A. Plots show
 353 accuracy of the ridge regression for predicting the task at retrieval when trained to discriminate the tasks at encoding
 354 (chance = 0). Mean accuracy across feature set sizes is shown for each age group. B. Plots show the mean correlation
 355 distance metric between encoding and retrieval (within-task correlation - between-task correlation). Error bars represent
 356 the within-group standard error of the mean. See Materials and Methods for details of measures and Results for details
 357 of analyses.

358 Hippocampus

359 In HC, ridge analysis showed reduced memory specificity in the older group ($F(1,30) =$
360 $6.50, p = 0.016$). There was also a positive association between memory specificity and memory
361 performance (for $Pr, F(1,27) = 8.77, p = 0.006$) and a marginal age-related difference in this
362 association (for group $\times Pr, F(1,27) = 3.12, p = 0.089$). The presence of robust group differences in
363 the association between memory specificity and memory performance was confirmed by a direct
364 comparison between task specificity at encoding (for which brain-behavior associations were non-
365 significant; see last section) and memory specificity. This revealed a significant interaction between
366 task phase, group and Pr ($F(1,27) = 4.59, p = 0.041$). Correlation analysis replicated the interaction
367 of group with memory performance (for group $\times Pr, F(1,26) = 6.17, p = 0.019$). In the young only,
368 memory specificity was robust for both measures ($F(1,14) = 10.93, p = 0.005$ for ridge; $F(1,15) =$
369 5.75 , for correlation, $p = 0.030$) and was positively associated with performance ($F(1,14) = 10.86, p$
370 $= 0.005$ for ridge; $F(1,14) = 9.71, p = 0.008$ for correlation).

371 Posterior cortex

372 There were no reliable age-related differences in memory specificity in the posterior ROIs
373 on Placebo. In FusG, ridge analysis did not show reliable age-related differences in memory
374 specificity ($F(1,30) = 2.57, p = 0.119$), nor significant brain-behavior associations (for $Pr, F(1,27) =$
375 $4.01, p = 0.056$; for group $\times Pr, F(1,27) = 3.82, p = 0.062$). As in RIFG, analysis across neural
376 specificity measures for both task phases showed a positive overall relation with individual
377 performance across age groups (for Pr main effect, $F(1,27) = 6.23, p = 0.019$; for interaction with
378 task phase, $F = 1.23$).

379 In LSOG, memory specificity was age-invariant (for group, $F < 1$) and robust across age
380 groups (for intercept across age groups $F(1,30) = 38.73, p < 0.001$ for ridge, $F(1,30) = 28.43, p <$
381 0.001 for correlation). It did not vary with individual memory performance ($F < 1$ for Pr effects).


382 Multi-voxel pattern analysis: dopaminergic drug effects

383 *Encoding phase: task specificity*

384 There was a pronounced age-invariant dopaminergic modulation of the ridge measure of
385 task specificity in all ROIs (see Table 1; for drug, min $F = 22.68$, max $p < 0.001$; for group \times drug,
386 max $F = 1.11$, min $p = 0.335$). In both age groups, task specificity was increased by both Sulpiride
387 and Bromocriptine relative to Placebo (for pairwise contrasts, all $p < 0.001$). However, no age-
388 dependent dopaminergic effects were observed. The drugs did not modulate brain-behavior
389 relations.

ROI (# voxels)/ Drug session	Younger group			Older group		
	Sulpiride	Placebo	Bromocriptine	Sulpiride	Placebo	Bromocriptine
LIFG (500)	0.93 (0.03)	0.84 (0.07)	0.92 (0.05)	0.92 (0.05)	0.82 (0.07)	0.90 (0.06)
RIFG (500)	0.89 (0.08)	0.80 (0.09)	0.89 (0.09)	0.90 (0.06)	0.77 (0.08)	0.90 (0.06)
LMFG (500)	0.92 (0.06)	0.83 (0.06)	0.92 (0.05)	0.92 (0.04)	0.83 (0.05)	0.91 (0.06)
RMFG (500)	0.92(0.06)	0.84 (0.06)	0.92 (0.05)	0.92 (0.07)	0.82 (0.07)	0.92 (0.04)
HC (50)	0.84 (0.07)	0.69 (0.04)	0.83 (0.07)	0.83 (0.09)	0.72 (0.07)	0.85 (0.08)

LSOG (150)	0.88 (0.05)	0.73 (0.08)	0.88 (0.08)	0.88 (0.06)	0.77 (0.09)	0.87 (0.09)
FusG (150)	0.86 (0.06)	0.78 (0.06)	0.87 (0.06)	0.87 (0.09)	0.78 (0.06)	0.88 (0.07)



390 Table 1. Drug effects on encoding phase task specificity (ridge regression). Means (SDs) are given for analyses
 391 of the selected feature sets in the Sulpiride, Placebo and Bromocriptine conditions (see Table 1).

392 *Memory specificity*

393 In hippocampus there was a dopaminergic modulation of the age-related differences in
 394 memory specificity which varied with individual differences in memory performance, illustrated in
 395 Figure 3. Memory specificity did not show reliable dopaminergic effects in PFC or posterior ROIs;
 396 details of these analyses are not reported (summary data for all ROIs are given in Supplementary
 397 Tables 2 and 3).

398 Ridge analysis in hippocampus revealed that young and old groups differed in drug effects
 399 on the association of memory specificity with *Pr* (see Fig. 3; for group x drug x *Pr*, $F(1.7,43.3) =$
 400 6.85 , $p = 0.004$; for drug x *Pr*, $F(1.7,43.3) = 4.49$, $p = 0.022$; for group x drug, $F(1.8,51.7) = 2.54$, p
 401 $= 0.095$). The correlation analysis replicated the interaction of group with drug and *Pr* ($F(2.0,50.9)$
 402 $= 4.66$, $p = 0.014$). Critically, as for the baseline age-related effects, direct comparison between the
 403 ridge neural specificity measures in the two task phases showed that the age-dependent modulation
 404 of memory specificity was distinct from the age-invariant modulation of encoding phase task
 405 specificity described above for HC and in the other ROIs (for task phase x drug x group x *Pr*,
 406 $F(1.6,42.8) = 5.66$, $p = 0.010$).

407
 408 Figure 3. Dopaminergic modulation of memory specificity in hippocampus assessed using ridge regression. A.
 409 Scatter plots show the relation between memory specificity (y-axis) and baseline individual memory performance – (x-
 410 axis) in young and older age groups in the 3 drug conditions. Baseline individual memory performance is indexed by *Pr*
 411 on Placebo. Best fit regression lines of memory specificity to Baseline *Pr* within each age group and drug condition
 412 are also shown (note that although raw *Pr* values are given here, ANCOVA analyses used within-group mean corrected *Pr*
 413 values; see Results). B. The bar graph shows mean memory specificity for each age group and drug condition. Error
 414 bars represent the within-group standard errors.

415
 416 *Post hoc* tests in the young revealed dopaminergic modulation of memory specificity
 417 regardless of performance (for drug, $F(1.6,22.2) = 4.42$, $p = 0.031$), with a quadratic trend reflecting
 418 reduction in memory specificity on both Sulpiride and Bromocriptine relative to Placebo ($F(1,14) =$
 419 8.02 , $p = 0.013$). This group also showed a dopamine-insensitive positive relation between memory
 420 specificity and memory performance (for *Pr* main effect, $F(1,14) = 8.16$, $p = 0.013$; for drug x *Pr*, F

421 = 2.32, $p = 0.130$). In the older group, drug effects varied according to individual differences in
422 memory performance (for drug x Pr , $F(1.7,20.7) = 6.96$, $p = 0.006$ for ridge and $F(1.8,21.6) = 6.90$,
423 $p = 0.006$ for replication with correlation metric), with a clear linear trend from the Sulpiride
424 through Placebo to the Bromocriptine condition ($F(1,12) = 10.62$, $p = 0.007$ for ridge, $F(1,12) =$
425 15.05 , $p = 0.002$ for correlation).

426 Within the older group, this memory specificity effect also differed reliably from any drug
427 effects on encoding phase task specificity (for task phase x drug x Pr , $F(1.8,22.0) = 5.01$, $p =$
428 0.018). The only discrepancy between the ridge and correlation indices of memory specificity was
429 that although both showed a strong linear trend, the ridge measure suggested a predominant
430 Bromocriptine effect (see Figure 3; for pairwise comparison with Placebo for drug x Pr , $F(1,12) =$
431 12.63 , $p = 0.004$ for ridge; $F(1,12) = 1.53$, $p = 0.240$ for correlation), while the correlation metric
432 suggested a predominant Sulpiride effect ($F(1,12) = 6.62$, $p = 0.024$ for correlation; $F < 1$ for ridge).
433 While on Placebo memory specificity did not vary with performance in the older group ($F < 1$ for
434 both measures), Bromocriptine induced a more negative association between memory specificity
435 and performance, with memory specificity increasing in poorer performers and decreasing in better
436 performers within the older group (for Pr effect on Bromocriptine $F(1,12) = 7.56$, $p = 0.018$ for
437 ridge; $F(1,12) = 1.24$, $p = 0.288$ for correlation). Sulpiride had the opposite effect, inducing a more
438 positive association of memory specificity and Pr ($F(1,12) = 3.27$, $p = 0.096$ for ridge, $F(1,12) =$
439 11.01 , $p = 0.006$ for correlation).

440 *Post hoc* tests were also conducted with individual linear drug effects on memory specificity
441 as the dependent measure (on Bromocriptine - Sulpiride). These confirmed reliable interactions of
442 age group and Pr (for ridge, $F(1,26) = 11.77$, $p = .022$; for correlation, $F(1,26) = 6.55$, $p = .017$).
443 Analyses of the relations between linear performance effects (Pr on Bromocriptine – Sulpiride) and
444 linear drug effects did not reveal any significant effects ($F < 1$ for all).

445 Discussion

446 Our results show that contextual reinstatement during episodic memory retrieval is less
447 specific in older adults, as predicted by the dedifferentiation account of cognitive aging (Carp et al.,
448 2010b; Li et al., 2001; Park et al., 2004). The data support the proposal that age-related
449 dedifferentiation impacts on episodic memory and impairs memory specificity (Li et al., 2005; St-
450 Laurent et al., 2014). In both young and older age groups, highly specific distributed patterns of
451 neural activity distinguished the processing of semantic and phonological task contexts during the
452 encoding phase, but reinstatement of these task-related patterns at retrieval – memory specificity –
453 was reduced in the older adults in PFC and hippocampus. This reduction in the distinctiveness of
454 retrieved representations was not accounted for by age-related differences in the specificity with
455 which the original task contexts were represented. Task specificity and memory specificity also
456 showed dissociable dopaminergic sensitivity with age-invariant and age-dependent effects,
457 respectively. In hippocampus, memory specificity varied linearly with dopamine stimulation in the
458 older group and this modulation tracked individual differences in memory performance. The
459 dopaminergic effect in hippocampus was distinct from a generalized age-invariant increase in task
460 specificity on both Sulpiride and Bromocriptine. Our data support the notion that dopaminergic
461 function in old age impacts hippocampal memory processes (Chowdhury et al., 2012; Kaasinen et
462 al., 2000; Morcom et al., 2010; Stemmelin et al., 2000; Wilson et al., 2006).

463 Findings in hippocampus under Placebo were as predicted. The robust reinstatement of task-
464 specific activity during episodic retrieval in the young group is consistent with recent reports that
465 elements of specific memory traces within the hippocampus are reactivated during recollection
466 (Chadwick et al., 2011; Staresina et al., 2012; but see Ritchey et al., 2012), although at the current
467 spatial resolution activity in adjacent cortical regions cannot be excluded. Hippocampal
468 reinstatement was not detectable in the older adults, even though distinctiveness of the original two
469 task contexts was, if anything, slightly greater in this group. This is the first report of an age-related
470 reduction in memory specificity in hippocampus and the first to use trial-unique stimuli, converging
471 with recent findings in cortical regions for reinstatement at the level of individual items (St-Laurent
472 et al., 2014). Models of hippocampal function specify that it is critical for the pattern separation of
473 distinct memory traces for highly similar events and their later reinstatement by pattern completion
474 (Marr, 1982; O'Reilly and McClelland, 1994; Treves and Rolls, 1994), functions which appear to be
475 compromised in aging (Wilson et al., 2006; Yassa et al., 2010).

476 It is important to note that the group difference in neural memory specificity did not reflect a
477 simple absence of recollection in the older adults: recollective experience was just as likely in this
478 group, and received the same boost from semantic as opposed to phonological processing. Instead,
479 the findings indicate a reduction in the distinctiveness of reinstatement assumed to support
480 contextual recollection (Danker and Anderson, 2010; St-Laurent et al., 2014). Recovery of episodic
481 detail is typically impoverished in older adults even when subjective recollection occurs (e.g.
482 (Levine et al., 2002). Our findings indicate that the decline in recollection of episodic detail in old
483 age (Schacter et al., 1997; Spencer and Raz, 1995) is accompanied by a reduction in the
484 distinctiveness of contextual representations. The data suggest an age-related reduction in the
485 specificity of hippocampal encoding, storage and/or retrieval of these representations which impacts
486 on their later reinstatement during recollection.

487 Age-related reductions in memory specificity in left dorsolateral and ventrolateral PFC were
488 prominent while memory specificity was age-invariant in LSOG. However, the data do not
489 necessarily suggest selective anterior changes as predicted by the frontal aging hypothesis (West,
490 1996): although group differences were not clear cut in fusiform gyrus, memory specificity in that
491 region was numerically greater in the young and non-significant in the older adults, consistent with
492 other studies (Carp et al., 2010a; Carp et al., 2011; Carp et al., 2010b; Goh et al., 2010; Park et al.,
493 2010; Park et al., 2012; St-Laurent et al., 2014). Critically, as in hippocampus, the group differences
494 in cortical memory specificity were task-dependent: representations of task context in the encoding
495 phase were well-differentiated in both age groups, unlike contextual reinstatement. It is fundamental
496 to the neural dedifferentiation hypothesis that less differentiated representations be able to explain
497 the marked age-related declines in higher-order functions, notably fluid intelligence, processing
498 speed and – as examined in the present study – episodic memory (Li et al., 2001). Our results
499 support this proposal, as do recent demonstrations of associations between neural category-
500 specificity in older adults and fluid processing (Park et al., 2010), working memory load (Carp et
501 al., 2010a), and episodic memory rather than perception (St-Laurent et al., 2014). In terms of brain-
502 behavior relations, the present study also shows for the first time an association between an index of
503 representation specificity and task performance which is age-dependent. This is consistent with the
504 assumption of the dedifferentiation account that decline in specificity accounts of age-related
505 cognitive change.

506 The results of our psychopharmacological manipulation provide some support for the theory
507 that a decline in dopamine transmission underpins age-related dedifferentiation (Li et al., 2001). In
508 hippocampus, Sulpiride induced greater memory specificity in older adults whose memory was
509 better at baseline (on Placebo) relative to those whose memory was poorer. The resulting brain-
510 behavior association for the group as a whole on Sulpiride resembled that in the young on Placebo.
511 Conversely, Bromocriptine induced a negative association of memory specificity and memory
512 performance in the older group, boosting memory specificity in poorer relative to better performers
513 (see Fig. 3). This partially supports our first prediction, and our prior findings (Morcom et al.,
514 2010), indicating an association between dopaminergic-sensitivity of memory processing and
515 individual memory ability in older adults only. However this association did not involve just a
516 greater sensitivity in poorer performers, but a varying pattern of response according to baseline
517 level of performance. While consistent with the dopamine hypothesis of aging, this does not fit the
518 simple view that dopaminergic decline both reduces memory performance and increases dopamine
519 sensitivity via a single mechanism. This result is considered in more detail below. The finding of an
520 age- and individual performance-related dopaminergic modulation of hippocampal memory
521 specificity, and the findings of Morcom et al. (2010), are also in line with recent behavioral genetics
522 data which implicate individual differences in dopamine receptor and transporter genotypes in
523 individual differences in episodic memory in later life (Li et al., 2013; Papenberg et al., 2013;
524 Papenberg et al., 2014).

525 As noted in the Introduction, we previously found that encoding phase activity in the older
526 group in MTL predicted later forgetting rather than remembering, and proposed that older adults
527 may encode less distinctive memory representations which may not support specific recollection
528 (Morcom et al., 2010). This is consistent with the current findings under Placebo. However, the
529 dopaminergic effects in the present study suggest a need for modification of our previous account of
530 the subsequent forgetting effects. This predicts that an intervention which enhances the subsequent
531 forgetting effects would also tend to reduce memory specificity. However, Bromocriptine increased
532 memory specificity in older adults with poorer memory at the same time as enhancing subsequent
533 forgetting effects (see Fig. 3). The latter effects may instead reflect a form of “partial
534 compensation”, which may improve subsequent memory specificity when it is engaged but may be
535 engaged only when there has been some underlying loss of memory function (Daselaar and Cabeza,
536 2005; de Chastelaine et al., 2011; Morcom and Johnson, in press). This would be in keeping with
537 the linear increase in memory performance in the older group with the increase in dopamine
538 signaling, alongside the subsequent forgetting effects in the older group, i.e., association of activity
539 in this region with unsuccessful encoding (although the behavioral effect did not vary reliably with
540 individual differences in performance).

541 The dopaminergic modulation of distributed task-specific activity in the encoding phase was
542 unexpected, with age-invariant increases under both Sulpiride and Bromocriptine. There were no
543 accompanying behavioral effects on the phonological and semantic decisions, although the age-
544 invariant Sulpiride effect on decision criterion in the memory task may reflect neuromodulatory
545 mechanisms also affecting processing during one or both of the two orienting tasks. The task
546 specificity measure was included as a baseline for the memory specificity measure, and likely
547 reflected a range of linguistic, mnemonic and executive processes engaged in the two tasks. In
548 pharmacological neuroimaging, nonspecific effects of drugs such as modulations of cerebral blood

549 flow are a potential concern (Honey and Bullmore, 2004). These seem unlikely to account for
550 highly process-specific effects such as those on memory specificity, but might contribute to the
551 widespread effects on task specificity. Whatever the nature of the latter effect, the critical point for
552 interpretation of the episodic memory findings is that the age-dependent dopaminergic modulation
553 of memory specificity in hippocampus differed clearly from the age-invariant effects on task
554 specificity. The performance-related drug effects in the older group only are consistent with the
555 literature suggesting age-related changes in dopaminergic neuromodulation and reveal a greater
556 general sensitivity to perturbations in dopamine signaling than in the young.

557 Our current and earlier investigations converge to support the possibility that age-related
558 memory impairment is associated with an imbalance in hippocampal dopaminergic regulation.
559 Older adults were more sensitive to dopaminergic perturbation than the young: D2-like blockade
560 was associated with improved memory function (greater hippocampal memory specificity) in better
561 older performers and D2-like stimulation with improved function in poorer performers. A
562 hippocampal locus of this effect is consistent with associations of aging and age-related memory
563 decline with loss of dopamine neurons and D2-like receptors in this region (Kaasinen et al., 2000)
564 (Stemmelin et al., 2000). Dopamine regulates hippocampal function by modulation of its cortical
565 inputs, directly via CA1 (Otmakhova and Lisman 1998) and indirectly via entorhinal cortex
566 (Pralong and Jones 1993; Caruana et al. 2006). Thus the direction of effects may depend on cortical
567 inputs as well as baseline function (Fujishiro et al., 2005; Umegaki et al., 2001). Behavioral and
568 neuroimaging investigations in humans have found that D2-like modulation can enhance or impair
569 cognitive function according to baseline function (e.g., Mehta et al., 2005; Mehta et al., 2008;
570 Reeves et al., 2010), consistent with the literature on inverted U functions in PFC (see Cools and
571 D'Esposito, 2011) and their alteration in aging (Mattay et al., 2006), as well as with the present data.

572 Given the systemic dopaminergic manipulation, however, it is also possible that upstream
573 effects – for example in striatum – can explain the MTL responses (Honey and Bullmore, 2004;
574 Morcom et al., 2010). We found no evidence that the age-related differences in memory specificity
575 in PFC were mediated by changes in dopaminergic transmission (Braver et al., 2001; Li et al.,
576 2001). However, this null finding requires cautious interpretation. Future studies should investigate
577 the possibility that the critical age changes mediating memory dedifferentiation in lateral PFC
578 involve D1-like receptors which are numerous in this region (Bäckman et al., 2009). Whether or not
579 cortical dopaminergic decline impacts on episodic memory, our findings in MTL are at least a
580 marker of dopaminergic dysregulation, and hint that it may be possible to improve this regulation
581 by adjusting dopamine signaling. Future studies are needed to establish the behavioral as well as the
582 neural impact of such adjustments.

583 **Acknowledgements**

584 This research was funded mainly by a Fellowship to AMM from Research into Ageing, UK,
585 and by an RCUK Academic Fellowship at the University of Edinburgh. Some of the research was
586 conducted by Hunar Abdulrahman as part of a dissertation for the MSc in Neurosciences at the
587 University of Edinburgh. The research was also supported by a Human Brain Project grant from the
588 National Institute of Mental Health and the National Institute of Biomedical Imaging &
589 Bioengineering. PCF was supported by a Wellcome Trust Senior Fellowship in Clinical Science,
590 and by the Bernard Wolfe Health Neuroscience Fund. ETB is a part-time (50%) employee and
591 shareholder of GSK. AMM is a member of the University of Edinburgh Centre for Cognitive

592 Ageing and Cognitive Epidemiology, part of the cross-council Lifelong Health and Wellbeing
593 Initiative, Grant number G0700704/84698. We are grateful to members of the Wolfson Brain
594 Imaging Centre (Cambridge).

595 **References**

- 596 Alvarez, P., Squire, L.R., 1994. Memory consolidation and the medial temporal-lobe - a simple
597 network model. *Proc. Natl. Acad. Sci. USA.* 91, 7041-7045.
- 598 Ashburner, J., Friston, K.J., 1999. Nonlinear spatial normalization using basis functions. *Hum.*
599 *Brain Mapp.* 7, 254-266.
- 600 Backman, L., Nilsson, L.-G., 1996. Semantic Memory Functioning Across the Adult Life Span.
601 *European Psychol.* 1, 27-33.
- 602 Baltes, P.B., Lindenberger, U., 1997. Emergence of a powerful connection between sensory and
603 cognitive functions across the adult life span: A new window to the study of cognitive aging?
604 *Psychol. Aging* 12, 12-21.
- 605 Braver, T.S., Barch, D.M., Keys, B.A., Carter, C.S., Cohen, J.D., Kaye, J.A., Janowsky, J.S.,
606 Taylor, S.F., Yesavage, J.A., Mumenthaler, M.S., Jagust, W.J., Reed, B.R., 2001. Context
607 processing in older adults: evidence for a theory relating cognitive control to neurobiology in
608 healthy aging. *J. Exp. Psychol. Gen.* 130, 746-763.
- 609 Bäckman, L., Karlsson, S., Fischer, H., Karlsson, P., Brehmer, Y., Rieckmann, A., Macdonald,
610 S.W., Farde, L., Nyberg, L., 2009. Dopamine D(1) receptors and age differences in brain activation
611 during working memory. *Neurobiol. Aging.*
- 612 Bäckman, L., Nyberg, L., Lindenberger, U., Li, S.C., Farde, L., 2006. The correlative triad among
613 aging, dopamine, and cognition: current status and future prospects. *Neurosci. Biobehav. Rev.* 30,
614 791-807.
- 615 Caley, C. F., & Weber, S. S., 1995. Sulpiride: an antipsychotic with selective dopaminergic
616 antagonist properties. *Ann. Pharmacother.*, 29, 152-160.
- 617 Carp, J., Gmeindl, L., Reuter-Lorenz, P.A., 2010a. Age differences in the neural representation of
618 working memory revealed by multi-voxel pattern analysis. *Front. Hum. Neurosci.* 4.
- 619 Carp, J., Park, J., Hebrank, A., Park, D.C., Polk, T.A., 2011. Age-Related Neural Dedifferentiation
620 in the Motor System. *PLoS ONE* 6.
- 621 Carp, J., Park, J., Polk, T.A., Park, D.C., 2010b. Age differences in neural distinctiveness revealed
622 by multi-voxel pattern analysis. *Neuroimage* 56, 736-743.
- 623 Chadwick, M.J., Hassabis, D., Maguire, E.A., 2011. Decoding overlapping memories in the medial
624 temporal lobes using high-resolution fMRI. *Learn. Memory* 18, 742-746.
- 625 Chowdhury, R., Guitart-Masip, M., Bunzeck, N., Dolan, R.J., Düzel, E., 2012. Dopamine
626 Modulates Episodic Memory Persistence in Old Age. *J. Neurosci.* 32, 14193-14204.
- 627 Cocosco, C.A., Kollokian, V., Kwan, R.K.S., Evans, A.C., 1997. Brainweb: online interface to a 3D
628 MRI simulated brain database. *Neuroimage* 5, 425.
- 629 Cools, R., D'Esposito, M., 2011. Inverted-U-Shaped Dopamine Actions on Human Working
630 Memory and Cognitive Control. *Biol. Psychiatry* 69, E113-E125.
- 631 Craik, F.I., Lockhart, R.S., 1972. Levels of processing: A framework for memory research. *J. Verb.*
632 *Learn. Verb. Behav.* 11, 671-684.
- 633 Danker, J.F., Anderson, J.R., 2010. The Ghosts of Brain States Past: Remembering Reactivates the
634 Brain Regions Engaged During Encoding. *Psychol. Bull.* 136.
- 635 Daselaar, S., Cabeza, R., 2005. Age-Related Changes in Hemispheric Organization. In: Cabeza, R.,
636 Nyberg, L., Park, D.C. (Eds.), *Cognitive Neuroscience of Aging: Linking Cognitive and Cerebral*
637 *Aging.* Oxford University Press, New York, pp. 325-353.

638 de Chastelaine, M., Wang, T.H., Minton, B., Muftuler, L.T., Rugg, M.D., 2011. The Effects of Age,
639 Memory Performance, and Callosal Integrity on the Neural Correlates of Successful Associative
640 Encoding. *Cereb. Cortex* 21.

641 Fujishiro, H., Umegaki, H., Suzuki, Y., Oohara-Kurotani, S., Yamaguchi, Y., Iguchi, A., 2005.
642 Dopamine D-2 receptor plays a role in memory function: implications of dopamine-acetylcholine
643 interaction in the ventral hippocampus. *J. Psychopharmacol.* 182, 253-261.

644 Gardiner, J.M., 1988. Functional aspects of recollective experience. *Mem Cognit.* 16, 309-313.

645 Goh, J.O., Suzuki, A., Park, D.C., 2010. Reduced neural selectivity increases fMRI adaptation with
646 age during face discrimination. *Neuroimage* 51, 336-344.

647 Haxby, J.V., Gobbini, M.I., Furey, M.L., Ishai, A., Schouten, J.L., Pietrini, P., 2001. Distributed
648 and overlapping representations of faces and objects in ventral temporal cortex. *Science* 293, 2425-
649 2430.

650 Hofer, S.M., Sliwinski, M.J., 2001. Understanding ageing - An evaluation of research designs for
651 assessing the interdependence of ageing-related changes. *Gerontology* 47.

652 Honey, G., Bullmore, E., 2004. Human pharmacological MRI. *Trends Pharm. Sci.* 25, 366-374.

653 Johnson, J.D., McDuff, S.G.R., Rugg, M.D., Norman, K.A., 2009. Recollection, Familiarity, and
654 Cortical Reinstatement: A Multivoxel Pattern Analysis. *Neuron* 63, 697-708.

655 Kaasinen, V., Vilkmann, H., Hietala, J., Nagren, K., Helenius, H., Olsson, H., Farde, L., Rinne, J.O.,
656 2000. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain.
657 *Neurobiol. Aging* 21, 683-688.

658 Kuhl, B.A., Rissman, J., Chun, M.M., Wagner, A.D., 2011. Fidelity of neural reactivation reveals
659 competition between memories. *Proc. Natl. Acad. Sci. USA* 108, 5903-5908.

660 Levine, B., Svoboda, E., Hay, J.F., Winocur, G., Moscovitch, M., 2002. Aging and
661 autobiographical memory: Dissociating episodic from semantic retrieval. *Psychol. Aging* 17, 677-
662 689.

663 Li, S.C., Lindenberger, U., Sikstrom, S., 2001. Aging cognition: from neuromodulation to
664 representation. *Trends Cogn. Sci.* 5, 479-486.

665 Li, S.C., Naveh-Benjamin, M., Lindenberger, U., 2005. Aging neuromodulation impairs associative
666 binding - A neurocomputational account. *Psychol. Sci.* 16, 445-450.

667 Li, S.-C., Papenberg, G., Nagel, I.E., Preuschhof, C., Schroeder, J., Nietfeld, W., Bertram, L.,
668 Heekeren, H.R., Lindenberger, U., Baeckman, L., 2013. Aging magnifies the effects of dopamine
669 transporter and D2 receptor genes on backward serial memory. *Neurobiol. Aging* 34, 358-e1.

670 Luciana, M., Collins, P. F., & Depue, R. A., 1998. Opposing roles for dopamine and serotonin in
671 the modulation of human spatial working memory functions. *Cereb. Cortex*, 8, 218-226.

672 Marr, D., 1982. *Vision*. WH Freeman, San Francisco.

673 Mattay, V.S., Fera, F., Tessitore, A., Hariri, A.R., Berman, K.F., Das, S., Meyer-Lindenberg, A.,
674 Goldberg, T.E., Callicott, J.H., Weinberger, D.R., 2006. Neurophysiological correlates of age-
675 related changes in working memory capacity. *Neurosci. Letters* 392, 32-37.

676 McClelland, J.L., McNaughton, B.L., Oreilly, R.C., 1995. Why there are complementary learning-
677 systems in the hippocampus and neocortex - insights from the successes and failures of
678 connectionist models of learning and memory. *Psychol. Review.* 102, 419-457.

679 McDuff, S.G.R., Frankel, H.C., Norman, K.A., 2009. Multivoxel Pattern Analysis Reveals
680 Increased Memory Targeting and Reduced Use of Retrieved Details during Single-Agenda Source
681 Monitoring. *J. Neurosci.* 29.

682 Mehta, M.A., Hinton, E.C., Montgomery, A.J., Bantick, R.A., Grasby, P.M., 2005. Sulpiride and
683 mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional
684 memory and long-term memory in healthy volunteers. *J. Psychopharmacol.* 19, 29-38.

685 Mehta, M.A., Montgomery, A.J., Kitamura, Y., Grasby, P.M., 2008. Dopamine D2 receptor
686 occupancy levels of acute sulpiride challenges that produce working memory and learning
687 impairments in healthy volunteers. *J. Psychopharmacol. (Berl)* 196, 157-165.

688 Morcom, A.M., Bullmore, E.T., Huppert, F.A., Lennox, B., Praseedom, A., Linnington, H.,
689 Fletcher, P.C., 2010. Memory Encoding and Dopamine in the Aging Brain: A
690 Psychopharmacological Neuroimaging Study. *Cereb. Cortex* 20, 743-757.

691 Morcom, A.M., Johnson, W. Neural reorganization and compensation in aging. *J. Cognitive*
692 *Neurosci.* In press.

693 Müller, U., von Cramon, D. Y., & Pollmann, S., 1998. D1-versus D2-receptor modulation of
694 visuospatial working memory in humans. *J. Neurosci.*, 18, 2720-2728.

695 Nelson, H.E., 1982. The National Adult Reading Test (NART). NFER-Nelson, Windsor, Berkshire.

696 Oranje, B., Gispen-de Wied, C. C., Westenberg, H. G. M., Kemner, C., Verbaten, M. N., & Kahn,
697 R. S., 2004. Increasing dopaminergic activity: effects of L-dopa and bromocriptine on human
698 sensory gating. *J. Psychopharmacol.*, 18, 388-394.

699 O'Reilly, R.C., McClelland, J.L., 1994. Hippocampal conjunctive encoding, storage, and recall:
700 avoiding a trade-off. *Hippocampus* 4, 661-682.

701 Papenberg, G., Backman, L., Nagel, I.E., Nietfeld, W., Schroeder, J., Bertram, L., Heekeren, H.R.,
702 Lindenberger, U., Li, S.-C., 2013. Dopaminergic Gene Polymorphisms Affect Long-term
703 Forgetting in Old Age: Further Support for the Magnification Hypothesis. *J. Cogn. Neurosci.* 25,
704 571-579.

705 Papenberg, G., Baeckman, L., Nagel, I.E., Nietfeld, W., Schroeder, J., Bertram, L., Heekeren, H.R.,
706 Lindenberger, U., Li, S.-C., 2014a. COMT Polymorphism and Memory Dedifferentiation in Old
707 Age. *Psychol. Aging* 29, 374-383.

708 Park, D.C., Polk, T.A., Park, R., Minear, M., Savage, A., Smith, M.R., 2004. Aging reduces neural
709 specialization in ventral visual cortex. *Proc. Natl. Acad. Sci. USA* 101, 13091-13095.

710 Park, J., Carp, J., Hebrank, A., Park, D.C., Polk, T.A., 2010. Neural Specificity Predicts Fluid
711 Processing Ability in Older Adults. *J. Neurosci.* 30, 9253-9259.

712 Park, J., Carp, J., Kennedy, K.M., Rodrigue, K.M., Bischof, G.N., Huang, C.-M., Rieck, J.R., Polk,
713 T.A., Park, D.C., 2012. Neural Broadening or Neural Attenuation? Investigating Age-Related
714 Dedifferentiation in the Face Network in a Large Lifespan Sample. *J. Neurosci.* 32.

715 Payer, D., Marshuetz, C., Sutton, B., Hebrank, A., Welsh, R.C., Park, D.C., 2006. Decreased neural
716 specialization in old adults on a working memory task. *Neuroreport* 17, 487-491.

717 Polyn, S.M., Natu, V.S., Cohen, J.D., Norman, K.A., 2005. Category-specific cortical activity
718 precedes retrieval during memory search. *Science* 310, 1963-1966.

719 Reddymasu, S. C., Soykan, I., & McCallum, R. W., 2007. Domperidone: review of pharmacology
720 and clinical applications in gastroenterology. *Am. J. Gastroenterol.*, 102, 2036-2045.

721 Reeves, S., Mehta, M., Howard, R., Grasby, P., Brown, R., 2010. The dopaminergic basis of
722 cognitive and motor performance in Alzheimer's disease. *Neurobiol. Disease* 37, 477-482.

723 Ritchey, M., Wing, E.A., Labar, K.S., Cabeza, R., 2012. Neural Similarity Between Encoding and
724 Retrieval is Related to Memory Via Hippocampal Interactions. *Cereb. Cortex*.

725 Schacter, D.L., Koutstaal, W., Norman, K.A., 1997. False memories and aging. *Trends Cogn. Sci.*
726 1, 229-236.

727 Snodgrass, J.G., Corwin, J., 1988. Pragmatics of measuring recognition memory: applications to
728 dementia and amnesia. *J. Exp. Psychol.* 117, 34-50.

729 Spencer, W.D., Raz, N., 1995. Differential effects of aging on memory for content and context: a
730 meta-analysis. *Psychol. Aging* 10, 527-539.

731 St-Laurent, M., Abdi, H., Bondad, A., Buchsbaum, B.R., 2014. Memory Reactivation in Healthy
732 Aging: Evidence of Stimulus-Specific Dedifferentiation. *J. Neurosci.* 34, 4175-4186.

- 733 Staresina, B.P., Henson, R.N.A., Kriegeskorte, N., Alink, A., 2012. Episodic Reinstatement in the
734 Medial Temporal Lobe. *J. Neurosci.* 32, 18150-18156.
- 735 Stemmelin, J., Lazarus, C., Cassel, S., Kelche, C., Cassel, J.C., 2000. Immunohistochemical and
736 neurochemical correlates of learning deficits in aged rats. *Neuroscience* 96, 275-289.
- 737 Talairach, J., Tournoux, P., 1988. *Co-Planar Stereotaxic Atlas of the Human Brain*. George Thieme
738 Verlag, Stuttgart.
- 739 Treves, A., Rolls, E.T., 1994. Computational analysis of the role of the hippocampus in memory.
740 *Hippocampus* 4, 374-391.
- 741 Umegaki, H., Munoz, J., Meyer, R.C., Spangler, E.L., Yoshimura, J., Ikari, H., Iguchi, A., Ingram,
742 D.K., 2001. Involvement of dopamine D-2 receptors in complex maze learning and acetylcholine
743 release in ventral hippocampus of rats. *Neuroscience* 103, 27-33.
- 744 Von Bahr, C., Wiesel, F. A., Movin, G., Eneroth, P., Jansson, P., Nilsson, L., & Ogenstad, S., 1991.
745 Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and
746 male volunteers. *Psychopharmacology*, 103, 443-448.
- 747 Wagner, A.D., Davachi, L., 2001. Cognitive neuroscience: forgetting of things past. *Curr. Biol.* 11,
748 R964-R967.
- 749 West, R.L., 1996. An application of prefrontal cortex function theory to cognitive aging. *Psychol.*
750 *Bull.* 120, 272-292.
- 751 Wiesel, F. A., Alfredsson, G., Ehrnebo, M., & Sedvall, G., 1982. Prolactin response following
752 intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations.
753 *Psychopharmacology*, 76, 44-47.
- 754 Wilson, I.A., Gallagher, M., Eichenbaum, H., Tanila, H., 2006. Neurocognitive aging: prior
755 memories hinder new hippocampal encoding. *Trends Neurosci.* 29, 662-670.
- 756